Search

Displaying results 1761 - 1770 of 8170 in total
  1. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    Concizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy.

  2. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G).

  3. Drug

    Subasumstat

    go.drugbank.com/drugs/DB16406
    Investigational

    Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced

  4. Drug

    Anisindione

    go.drugbank.com/drugs/DB01125
    Approved

    Anisindione is a synthetic anticoagulant and an indanedione derivative.

    Synonyms: 2-p-Anisyl-1,3-indandione, 2-(p-Methoxyphenyl)-1,3-indandione
  5. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA ap...

    Categories: Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2C19 Inhibitors
  6. Drug

    PF-00489791

    go.drugbank.com/drugs/DB11736
    Investigational

    PF-00489791 has been used in trials studying the treatment of Hypertension, Raynaud's Disease, Diabetic Nephropathies, Hypertension, Pulmonary, and Peripheral Vascular Disease.

  7. Drug

    Ciforadenant

    go.drugbank.com/drugs/DB16125
    Investigational

    Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).

  8. Drug

    Prussian blue

    go.drugbank.com/drugs/DB06783
    Approved

    It is insoluble in water but also tends to form a colloid thus can exist in either colloidal or water-soluble form, and an insoluble form. … It is orally administered for clinical purposes to be used as an antidote for certain kinds of heavy metal poisoning, such as thallium and radioactive isotopes of caesium.

  9. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma. … antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a self-inactivating lentiviral vector (LV) expressing an

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE
  10. Drug

    Cyclizine

    go.drugbank.com/drugs/DB01176
    ApprovedWithdrawn

    A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors